Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in the United Kingdom

被引:14
作者
Burn, Edward [1 ,2 ]
Li, Xintong [2 ]
Delmestri, Antonella [2 ]
Jones, Nathan [2 ]
Duarte-Salles, Talita [1 ]
Reyes, Carlen [1 ]
Martinez-Hernandez, Eugenia [3 ,4 ]
Marti, Edelmira [5 ]
Verhamme, Katia M. C. [6 ]
Rijnbeek, Peter R. [6 ]
Strauss, Victoria Y. [2 ]
Prieto-Alhambra, Daniel [2 ,6 ]
机构
[1] Fundacio Inst Univ Recerca Atencio Primaria Salut, Barcelona, Spain
[2] Univ Oxford, Ctr Stat Med CSM, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England
[3] Hosp Clin Barcelona, Dept Neurol, Barcelona, Spain
[4] Univ Barcelona, Barcelona, Spain
[5] Hosp Clin Univ Valencia, Hematol Dept, Hemostasis & Thrombosis Unit, Valencia, Spain
[6] Erasmus MC, Dept Med Informat, Rotterdam, Netherlands
关键词
IMMUNE; IMMUNIZATION; PURPURA;
D O I
10.1038/s41467-022-34668-w
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Population-based studies can provide important evidence on the safety of COVID-19 vaccines. Using data from the United Kingdom, here we compare observed rates of thrombosis and thrombocytopenia following vaccination against SARS-CoV-2 and infection with SARS-CoV-2 with background (expected) rates in the general population. First and second dose cohorts for ChAdOx1 or BNT162b2 between 8 December 2020 and 2 May 2021 in the United Kingdom were identified. A further cohort consisted of people with no prior COVID-19 vaccination who were infected with SARS-Cov-2 identified by a first positive PCR test between 1 September 2020 and 2 May 2021. The fourth general population cohort for background rates included those people in the database as of 1 January 2017. In total, we included 3,768,517 ChAdOx1 and 1,832,841 BNT162b2 vaccinees, 401,691 people infected with SARS-CoV-2, and 9,414,403 people from the general population. An increased risk of venous thromboembolism was seen after first dose of ChAdOx1 (standardized incidence ratio: 1.12 [95% CI: 1.05 to 1.20]), BNT162b2 (1.12 [1.03 to 1.21]), and positive PCR test (7.27 [6.86 to 7.72]). Rates of cerebral venous sinus thrombosis were higher than otherwise expected after first dose of ChAdOx1 (4.14 [2.54 to 6.76]) and a SARS-CoV-2 PCR positive test (3.74 [1.56 to 8.98]). Rates of arterial thromboembolism after vaccination were no higher than expected but were increased after a SARS-CoV-2 PCR positive test (1.39 [1.21 to 1.61]). Rates of venous thromboembolism with thrombocytopenia were higher than expected after a SARS-CoV-2 PCR positive test (5.76 [3.19 to 10.40]). Population-based studies can provide information on the safety of COVID-19 vaccines. Here the authors report the rates thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in the United Kingdom and compare them with the background (expected) rates in the general population.
引用
收藏
页数:10
相关论文
共 50 条
[41]   An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants [J].
Kayesh, Mohammad Enamul Hoque ;
Kohara, Michinori ;
Tsukiyama-Kohara, Kyoko .
VIRUSES-BASEL, 2021, 13 (11)
[42]   A New Butyrate Releaser Exerts a Protective Action against SARS-CoV-2 Infection in Human Intestine [J].
Paparo, Lorella ;
Maglio, Maria Antonia ;
Cortese, Maddalena ;
Bruno, Cristina ;
Capasso, Mario ;
Punzo, Erika ;
Ferrucci, Veronica ;
Lasorsa, Vito Alessandro ;
Viscardi, Maurizio ;
Fusco, Giovanna ;
Cerino, Pellegrino ;
Romano, Alessia ;
Troncone, Riccardo ;
Zollo, Massimo .
MOLECULES, 2022, 27 (03)
[43]   SARS-CoV-2 vaccination and practical points in psoriasis patients: A narrative review [J].
Aryanian, Zeinab ;
Balighi, Kamran ;
Hatami, Parvaneh ;
Goodarzi, Azadeh ;
Mohandesi, Nessa Aghazadeh ;
Afshar, Zeinab Mohseni .
DERMATOLOGIC THERAPY, 2022, 35 (05)
[44]   The Levels of SARS-CoV-2 Specific Antibodies in Human Milk Following Vaccination [J].
Juncker, Hannah G. ;
Mulleners, Sien J. ;
van Gils, Marit J. ;
de Groot, Christianne J. M. ;
Pajkrt, Dasja ;
Korosi, Aniko ;
van Goudoever, Johannes B. ;
van Keulen, Britt J. .
JOURNAL OF HUMAN LACTATION, 2021, 37 (03) :477-484
[45]   COVID-19 vaccination: Effects of immunodominant peptides of SARS-CoV-2 [J].
de Andrade, Arthur Gomes ;
Comberang, Fernando Cezar ;
Cavalcante-Silva, Luiz Henrique Agra ;
Kessen, Tatjana Souza Lima .
CYTOKINE, 2023, 170
[46]   Immunogenicity of SARS-CoV-2 mRNA intramuscular vaccination in patients with muscular disorders [J].
Kasai, Ryousuke ;
Funato, Michinori ;
Maruta, Kanako ;
Yasuda, Kunihiko ;
Minatsu, Hiroshi ;
Ito, Junji ;
Takahashi, Kazuhiro .
FRONTIERS IN IMMUNOLOGY, 2023, 14
[47]   Neonatal SARS-CoV-2 mRNA Vaccination Efficacy Is Influenced by Maternal Antibodies [J].
Schumer, Amy ;
Bonney, Elizabeth A. ;
Harby, Ethan ;
Majumdar, Devdoot .
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2024, 92 (04)
[48]   Is SARS-CoV-2 vaccination safe and effective for elderly individuals with neurodegenerative diseases? [J].
Shi, Yan ;
Guo, Minna ;
Yang, Wenjing ;
Liu, Shijiang ;
Zhu, Bin ;
Yang, Ling ;
Yang, Chun ;
Liu, Cunming .
EXPERT REVIEW OF VACCINES, 2021, 20 (04) :375-383
[49]   Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients [J].
Romano, Emanuela ;
Pascolo, Steve ;
Ott, Patrick .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (06)
[50]   Could BCG Vaccination Induce Protective Trained Immunity for SARS-CoV-2? [J].
Covian, Camila ;
Retamal-Diaz, Angello ;
Bueno, Susan M. ;
Kalergis, Alexis M. .
FRONTIERS IN IMMUNOLOGY, 2020, 11